Background: Resection and reconstruction of the inferior vena cava (IVC) is occasionally required in the surgical treatment of intra-abdominal tumours. IVC reconstruction can be performed with biological or synthetic graft material, with most centres preferring synthetic grafts. In spite of the potential advantages of biological grafts in terms of handling characteristics, and safety, very limited data are available about their use in patients requiring an IVC resection. Methods: Medical records of 32 patients who underwent an IVC resection and reconstruction from 1990 and 2011 with autogenous peritoneo-fascial (N = 22) and bovine pericardial (N = 10) grafts were reviewed.
Introduction
Several series have reported on the safety and satisfactory oncological outcomes of resection for tumours that originate from or infiltrate the inferior vena cava (IVC). [1] [2] [3] [4] [5] The optimal management of the IVC after resection is controversial, 6 with the use of patch or interposition grafting for IVC reconstruction the most commonly used approach. [1] [2] [3] [4] [5] A variety of materials, such as biological (autologous or heterologous) and synthetic materials, have been proposed as grafts for IVC reconstruction. 7 The synthetic material, polytetrafluoroethylene (PTFE) has become the most commonly used material for IVC replacement [1] [2] [3] [4] [5] because it is readily available and comes in a variety of diameters and lengths. Given the potential risk of infection and thrombosis of synthetic grafts, the optimal material for IVC reconstruction is still debated and the search for improved graft material is still ongoing. 7 Biological grafts have been proposed as an alternative to PTFE, because of their biocompatibility, reliable long-term patency and low risk of infection. 7, 8 However, data regarding the use of biologic grafts for reconstruction of the IVC are very limited. The use of two types of biological grafts, autogenous peritoneo-fascial (APF), and bovine pericardium for IVC reconstruction are described in the present study.
Patients and methods
The medical records of 32 patients who underwent IVC reconstruction with biological material between 1990 and 2011 were reviewed. Institutional review board approval was obtained for this study. Short-and long-term outcomes, cumulative patency of IVC replacement and survival were assessed. Reconstruction of the IVC was performed with an APF graft in 22 patients and bovine pericardium in 10 patients. No IVC reconstruction with a synthetic graft was performed during the study period. The creation of the conduit was carried out intra-operatively after the size of the patient's IVC was determined. When the APF graft was used, a flap of parietal peritoneum backed by the posterior rectus sheath was sharply dissected from the abdominal wall. The peritoneal surface was maintained on the luminal side and the graft wrapped around a 20-22 Fr cylindrical sizing device to obtain the appropriate diameter. Fashioning of the tube was completed by staple transection using a 60-mm linear cutting vascular stapler. The graft was then fixed with 2% glutaraldehyde solution soaked for 10 min and the glutaraldehyde was removed with serial dilution in isotonic saline. The technique used for the construction of the bovine pericardial graft is similar to APF. The bovine pericardial leaflet is wrapped around a cylindrical sizing device to obtain the appropriate diameter, and anastomosed longitudinally by a vascular linear cutting stapler ( Fig. 1) .
In all patients, the IVC was resected and repaired under total vascular exclusion. Isolated hypothermic perfusion was used selectively for patients with liver disease and where long clamp times were expected owing to the complexity of resection. The type of caval resection and reconstruction varied according to tumour infiltration of the IVC. A large number of patients were able to have primary closure of their IVC without the need for a graft and were not included in this study. When the IVC wall involvement was longitudinal and less than 30% of its circumference, a tangential resection with patch reconstruction was performed. When involvement of the IVC was greater than 40% of its circumference a caval segment was resected and replaced. The anastomosis was performed in a standard fashion with a continuous 3/0 polypropylene suture. Unfractionated heparin (5000 IU every 12 h) was administered subcutaneously after the operation until discharge. The patients were typically followed up every 3 months with a clinical examination, blood test and abdominal imaging [computed tomography (CT) or magnetic resonance imaging). At 1-year post-operatively, an individualized follow-up protocol according to the tumour and patient characteristics was used. Re-evaluation was done at the request of the primary physician or the oncology service based on clinical symptoms. Imaging was obtained if patients developed symptoms of IVC compression such as lower extremity oedema and scrotal oedema. Morbidity was classified according to Dindo-Clavien classification 9 and operative mortality was defined as any death occurring within 90 days after surgery. The results are presented as median and ranges.
Results
A total of 32 patients underwent IVC graft reconstruction with biological grafts during the study period. The demographic characteristics are listed in Table 1 . Indications for surgery were colorectal liver metastases in 5 patients, leiomyosarcoma in 8, renal cell cancer in 11, adrenal cancer in 2, hepatocellular carcinoma (HCC) in 1, intrahepatic cholangiocarcinoma in 2 and a gastrointestinal stromal tumour in 1. IVC resection was performed with an extended right hepatectomy in 4 patients, right hepatectomy in 2, extended left hepatectomy in 1, minor liver resection in 7, nephrectomy in 10 and pancreaticoduodenectomy in 2 patients. The median operating time was 400 min (180-620) and the median blood loss was 2000 ml (300-9000). A tangential resection with patch repair was performed in 10 patients, whereas in the remaining 22 it was necessary to resect and replace a circumferential segment, or all, of the retrohepatic IVC. Re-implantation of the renal or hepatic vein was performed in 10 patients.
Post-operative outcome
Six major complications (grade Ն 3a) occurred in six patients ( Table 2) . One patient died of multi-organ failure after the onset of acute respiratory distress syndrome and septic shock. The remaining two patients died of acute liver failure leading to multi-organ failure. In all these three patients, IVC replacement was associated with a major liver resection. Non-lethal complications (grade Ն 3a) in the other three patients included transient liver insufficiency, biliary fistula and sepsis. There were no early or late complications related to graft thrombosis or infection. Tumour infiltration of the IVC was observed during the pathological examination of the specimen in 24 patients, whereas in the remaining 8 patients the tumour was adherent to the IVC without infiltration. Follow-up CT scans were available for review in 26 of 32 patients at a median follow-up of 40 months after the IVC resection (Fig. 2) . No patients developed clinical signs of IVC compression or thrombosis. The overall survival at 1 and 5 years was 78% and 48%, respectively.
Discussion
The ideal material for IVC reconstruction remains controversial. 7 PTFE grafts have been reported to remain patent for several years, but there are disadvantages to the use of PTFE, with the need for long-term anticoagulation therapy and the risk of graft infection. Biological grafts have been proposed as an alternative to PTFE in cardiothoracic surgery for the reconstruction of the superior vena cava. 10 However, limited data are available about the use of biological grafts for the reconstruction of the IVC.
The use of biological tissues dates back to the early days of cardiovascular surgery, when the autologous vein was used in a coronary artery bypass. 7 A significant advance in the use of biological material came from the use of glutaraldehyde, which enhances the structural stability, eliminates the antigenicity and preserves the sterile tissue. 11 Bovine pericardium treated with glutaraldehyde is one of the biological materials widely used in cardiovascular surgery as a patch after arteriotomy and more recently for major venous reconstruction. The commercially available detoxified bovine pericardial flaps have strongly improved the graft biocompatibility, providing heterologous tissue comparable to autologous tissue. Bovine pericardium has several well-known features. It has lower risks of infection and thrombosis when compared with synthetic materials, and does not require longterm anticoagulation. 8, 11 The commercially available bovine pericardium is manufactured and processed to a consistent nominal 0.5 mm thickness, this reliable consistency makes it easy to suture the graft to the vascular wall and has little suture line bleeding after implantation. As bovine pericardium is a solid tissue, without air spaces, ultrasound can be immediately used after implantation to check for patency. 8 Furthermore, bovine pericardium is an acellular material, composed mainly of collagen, which facilitates host cell migration and proliferation, accelerating tissue regeneration and endothelialization. 7, 8 Finally, as bovine pericardium is a fixed tissue, it has the advantage of off-the-shelf availability with a cost significantly lower than PTFE grafts. Experimental use of peritonealized fascial grafts for the reconstruction of artery and veins was initially described in the late 1960s. 12 However, this graft was not considered for clinical practice until our group described the first experience in six patients. 13 APF is readily available and the harvesting and fashioning of the graft can be easily performed in a short time. Experimental data have demonstrated that the inner peritoneal mesothelial surface has a low thrombogenic potential and induces rapid endothelialization. 14, 15 Infection after IVC replacement with PTFE has been shown to be a rare occurrence in several large series. Even although the risk of PTFE graft infection is low, there is increased concern where IVC resection and reconstruction is performed in association with a bilioenteric, colonic or pancreatic anastomosis. 16 Furthermore, in spite of a patency rate between 89-100% being reported in large series of IVC reconstruction with PTFE, long-term anticoagulation was necessary. [1] [2] [3] [4] 17, 18 This has led some authors to propose the use of various forms of biological grafts including APF, bovine pericardium and sutured superficial femoral vein panel graft for IVC reconstruction because these biological grafts represent a safer alternative to PTFE. 13, [19] [20] [21] Furthermore, from a technical point of view both bovine pericardium and APF have many features, which compare favourably with PTFE. The grafts can be easily tailored to match the size of the native IVC even when the diameter at the top and bottom of the graft are different. These grafts have optimal handling features, minimal suture line bleeding and a lower cost.
The results of the present series demonstrate that the biological grafts used offer reliable long-term patency without permanent anticoagulation, and no complications related to graft thrombosis or infection. One limitation of this study is the absence of imaging to document long-term patency of the IVC reconstruction in six patients. Imaging for this review was available for 26 of the 32 patients at a median follow-up of 40 months after the IVC repair. However, there were no patients who developed signs or symp-toms of IVC obstruction. For the remaining living patients, the cumulative 3-year patency for IVC graft replacement, determined by imaging and/or clinical assessment was 100%. With the heterogeneity of tumour types included in the present series it is difficult to comment definitively on the oncological efficacy of this radical approach for individual cancer subsets. However, the overall 5-year survival of 48% clearly suggests that radical vena caval resection requiring reconstruction has an oncological benefit for this select group of patients who would otherwise have no chance of a cure.
The clinical results of this series are similar in many aspects to other recent series of IVC reconstruction with PTFE grafts. [1] [2] [3] [4] [5] However, biological grafts allow superior flexibility and greater biocompatability, especially in light of their easier handling and long-term patency without permanent anticoagulation. These clear advantages of biological grafts should lead to their wider use in IVC replacement surgery.
